Authors : Meghna Patel, Meghna Patel, Kaushal Bhavsar, Kaushal Bhavsar, Kiran Rami, Kiran Rami, Arvind Vala, Arvind Vala, Kalpita Shringarpure, Kalpita Shringarpure
DOI : 10.18231/j.ijirm.2019.051
Volume : 4
Issue : 4
Year : 2019
Page No : 221-223
Introduction and Aim: The World Health Organisation (WHO) TB statistics for India for 2016 give an
estimated incidence of 2.79 million cases. CBNAAT (Cartridge based nucleic acid amplification Test) helps
to diagnose upfront drug resistance within two hours of sample submission.
Materials and Methods: We collected data from RNTCP laboratory for all newly diagnosed cases of
Pulmonary TB registered from December 2018 to July 2019 who underwent sputum microscopy by LED
FM and CBNAAT testing.
Result: Out of 333 patients, 241 (72%) were sputum microscopy positive while CBNAAT detected
Mycobacterium TB (MTB) in 289 (86.8%) patients of whom Rifampicin resistance was detected among 15
patients (4.5%). This included 12/240 sputum positive patients in whom MTB was detected by CBNAAT
and 3/49 sputum negative patients in whom MTB was detected by CBNAAT. There is moderate agreement
for diagnosis of MTB by CBNAAT and sputum microscopy (Kappa = 0.55, CI: 0.449 to 0.655).
Conclusion: Universal upfront sputum CBNAAT in all new suspected cases of pulmonary TB according to
current guidelines of RNTCP shows moderate agreement with LED-FM and yields a elevated percentage
of patients being diagnosed with pulmonary sputum positive TB.
Keywords: New Pulmonary TB, Sputum Microscopy, CBNAAT, Drug Resistant TB.